dulaglutide vs semaglutide for weight loss what is the difference between and versus once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Dulaglutide vs. Semaglutide – Weight loss and muscle loss.

Key Players Competitive Landscape & Emerging Players Lexicon Pharmaceuticals: Lexicon has licensed its obesity drug candidate LX9851 to Novo Nordisk, with plans to explore its use in combination with semaglutide

Studies consistently show that patients comply better with weekly injections than daily ones

The main challenges include maintaining peptide stability, ensuring accurate impurity profiling, and achieving bioequivalence

To view or add a comment, sign in Today in #Employer Coverage: CMS has indefinitely postponed its BALANCE program that would have subsidized #GLP-1 obesity medications for Medicare members, a predictable outcome given the adverse selection risks and short-term cost challenges that make coverage financially untenable for health plans even at negotiated prices